Puma Biotechnology | PBYI - Ativo Circulante





Ativo Circulante Alterar Data
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Exelixis USD 1.44B 41.03M 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Incyte USD 5.02B 746.01M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Moderna USD 6.54B 54M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Takeda JPY 3.12T 195.82B 2025-12
TG Therapeutics USD 630.76M 31M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12